Management of Lymphopenia During Osimertinib Treatment

Risk Stratification and Monitoring

The American Society of Clinical Oncology recommends continuing osimertinib without dose modification for lymphopenia of any grade, unless the absolute lymphocyte count drops below 250/mm³ (Grade 4), in which case prophylactic measures should be initiated 1
For Grade 1-3 lymphopenia (≥250/mm³), continue osimertinib at full dose (80 mg daily) without modification, as this level of lymphopenia does not warrant intervention 1

When the absolute lymphocyte count falls below 250/mm³, implement Mycobacterium avium complex (MAC) prophylaxis, Pneumocystis jirovecii pneumonia (PCP) prophylaxis, CMV screening at regular intervals, HIV and hepatitis screening if not previously performed, and EBV testing if the patient develops lymphadenopathy, hepatitis, fevers, or hemolysis suggestive of lymphoproliferative disease 1

Monitor for signs of infection, particularly opportunistic infections in patients with Grade 4 lymphopenia, and educate patients to seek immediate care for fever >38.3°C (101°F), new infections, or worsening respiratory symptoms 2
The American Society of Clinical Oncology recommends not holding osimertinib for lymphopenia alone, but rather only if pancytopenia, severe thrombocytopenia, or severe anemia occurs concurrently, or if aplastic anemia is diagnosed 1

Do not routinely use G-CSF for isolated lymphopenia, as this is ineffective for lymphocyte recovery and is only indicated for severe neutropenia (ANC <1000/mm³) 2
Lymphopenia management focuses on infection prophylaxis rather than growth factor support, and patients can continue osimertinib safely with appropriate antimicrobial prophylaxis when lymphocyte counts are severely depressed 1